tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

MRKR Stock Latest News

Marker Therapeutics’ Promising Cancer Therapy Progress
Company AnnouncementsMarker Therapeutics’ Promising Cancer Therapy Progress
2M ago
MRKR
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
PremiumPress Releases
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
2M ago
MRKR
Marker Therapeutics initiated with a Buy at Ladenburg on post-CAR-T opportunity
PremiumThe Fly
Marker Therapeutics initiated with a Buy at Ladenburg on post-CAR-T opportunity
2M ago
MRKR
Marker Therapeutics initiated with a Buy at Ladenburg
PremiumThe Fly
Marker Therapeutics initiated with a Buy at Ladenburg
2M ago
MRKR
Marker Therapeutics’ MT-601 Shows Promising Results
PremiumCompany Announcements
Marker Therapeutics’ MT-601 Shows Promising Results
3M ago
MRKR
Marker Therapeutics announces presentation on Phase 1 APOLLO study
PremiumThe FlyMarker Therapeutics announces presentation on Phase 1 APOLLO study
3M ago
MRKR
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies 
PremiumPress Releases
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies 
3M ago
MRKR
Marker Therapeutics Advances in Immuno-Oncology
PremiumCompany Announcements
Marker Therapeutics Advances in Immuno-Oncology
3M ago
MRKR
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
PremiumPress Releases
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
3M ago
MRKR
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
PremiumPress Releases
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
4M ago
MRKR
Marker Therapeutics Ends Stock Sale Deal with LPC
PremiumCompany Announcements
Marker Therapeutics Ends Stock Sale Deal with LPC
4M ago
8K
MRKR
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
PremiumPress Releases
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
6M ago
MRKR
Marker receives approval from the USAN council, INN committee for neldaleucel
PremiumThe FlyMarker receives approval from the USAN council, INN committee for neldaleucel
6M ago
MRKR
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
PremiumPress Releases
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
6M ago
MRKR
Marker Therapeutics announces clinical program updates, pipeline prioritization
PremiumThe Fly
Marker Therapeutics announces clinical program updates, pipeline prioritization
6M ago
MRKR
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
PremiumPress Releases
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
7M ago
MRKR
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
7M ago
MOR
ACHV
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
7M ago
MOR
BPMC
Marker announces sustained complete response in patient treated with MT-601
PremiumThe Fly
Marker announces sustained complete response in patient treated with MT-601
7M ago
MRKR
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
PremiumPress ReleasesMarker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
8M ago
MRKR
option delistings on September 25th
PremiumThe Fly
option delistings on September 25th
9M ago
MFH
NYC
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
PremiumPress Releases
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
10M ago
MRKR

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >